Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.
Earnings per share decreased 45.71% over the past year to ($0.51), which were in line with the estimate of ($0.51).
Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $490,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 07, 2020
Time: 11:01 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/h3uyhwmi
Recent Stock Performance
Company's 52-week high was at $20.50
52-week low: $5.17
Price action over last quarter: down 10.36%
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.